razaxaban has been researched along with apixaban in 5 studies
| Studies (razaxaban) | Trials (razaxaban) | Recent Studies (post-2010) (razaxaban) | Studies (apixaban) | Trials (apixaban) | Recent Studies (post-2010) (apixaban) |
|---|---|---|---|---|---|
| 20 | 0 | 2 | 2,405 | 255 | 2,250 |
| Protein | Taxonomy | razaxaban (IC50) | apixaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, RS; He, K; Knabb, RM; Koch, S; Lam, PY; Luettgen, JM; Orwat, MJ; Pinto, DJ; Rendina, AR; Rossi, KA; Smallwood, A; Wexler, RR; Wong, PC; Xin, B | 1 |
| He, K; King, SR; Knabb, RM; Lam, PY; Luettgen, JM; Qiao, JX; Rendina, AR; Wexler, RR; Wong, PC; Xin, B | 1 |
| Alexander, RS; Amparo, E; Kish, K; Knabb, RM; Luettgen, JM; Morin, P; Pinto, DJ; Quan, ML; Rossi, KA; Sheriff, S; Smallwood, A; Wexler, RR; Woerner, FJ | 1 |
| Cheney, DL; Knabb, RM; Pinto, DJ; Smallheer, JM; Wexler, RR | 1 |
| Barrett, YC; Frost, C; Shenker, A; Wang, Z | 1 |
1 review(s) available for razaxaban and apixaban
| Article | Year |
|---|---|
Factor Xa inhibitors: next-generation antithrombotic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Hemostasis; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Thrombosis | 2010 |
4 other study(ies) available for razaxaban and apixaban
| Article | Year |
|---|---|
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation fa
Topics: Administration, Oral; Animals; Biological Availability; Blood Coagulation; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; In Vitro Techniques; Models, Molecular; Molecular Structure; Pyrazoles; Pyridones; Rabbits; Structure-Activity Relationship | 2007 |
Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
Topics: Animals; Caco-2 Cells; Factor Xa Inhibitors; Humans; Pyridones; Rabbits; Serine Proteinase Inhibitors; Structure-Activity Relationship | 2009 |
Phenyltriazolinones as potent factor Xa inhibitors.
Topics: Anticoagulants; Crystallography, X-Ray; Drug Design; Factor Xa Inhibitors; Humans; Isoxazoles; Models, Molecular; Molecular Structure; Pyrazoles; Pyridones; Sulfones | 2010 |
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Isoxazoles; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |